LONDON, April 30, 2015 /PRNewswire/ --
Opportunities for Leading Companies
Report Details
Drug discovery outsourcing - your guide to the commercial potential of services and companies in this market
Where is the drug discovery outsourcing market heading? Visiongain's new report gives you revenue predictions for the drug discovery outsourcing market and its submarkets from 2015 to 2025, helping you stay ahead.
Our new 223-page report provides 149 tables, charts, and graphs. Discover the growing trends of this industry. In particular, our new study lets you assess forecasted sales at overall world market and national level. You will see financial results, drivers and restraints, and revenue predictions.
Besides revenue forecast to 2025, this report provides you with market shares, business outlooks, qualitative analyses (including SWOT and Porter's Five Forces Analysis), company profiles and commercial partnerships. Also, read the full transcript of three exclusive expert opinion interviews to inform you about prospects for investments and sales:
- Dr. Mario Polywka, Chief Operating Officer, Evotec
- Dr. John Davis, Director of Discovery & Dave Roberts, Business Development Director, Radiochemistry, Selcia
- Dr. Paul Overton, Executive VP, Business Development & Marketing, Apuit
See revenue forecasts for leading drug discovery outsourcing sectors
Along with prediction of overall world market value to 2025, our report shows you revenue forecasting for the four services sectors at world level:
• Chemistry services market forecast 2015-2025
• Biology services market forecast 2015-2025
• Lead optimisation market forecast 2015-2025
• Lead identification and screening market forecast 2015-2025
The analysis helps you identify market potential with individual revenue forecasts, annual growth rates and CAGRs and market shares.
To see a report overview please email Sara Peerun on [email protected]
Discover prospects of the leading national markets for the drug discovery outsourcing
The drug discovery outsourcing market is becoming increasingly global as companies look to lower costs by off-shoring their work to CROs based in emerging economies.
You will discover individual revenue forecasts, annual growth rates, CAGRs, and market shares to 2025, as well as written supporting analyses for each of the 13 leading national markets and the rest of the world (RoW):
• US
• Japan
• Germany
• France
• UK
• Italy
• Spain
• China
• Brazil
• Russia
• India
• South Korea
• Mexico
• Rest of the World
Demand for CROs based in emerging markets will be a major driver of growth in this market.
Leading companies and potential for market growth
Our new study predicts the world market for drug discovery outsourcing will reach $16.6bn in 2015. There is the increasing trend for pharmaceutical and biotech companies to form partnerships and alliances with CROs during the early drug discovery phase.
Our research profiles leading companies, assessing their financial performance and products. You will see which organisations hold the greatest potential and what services each offer. See the profiles of 14 leading companies:
• Albany Molecular Research (AMRI)
• Aptuit
• Charles River Laboratories (Acquired Galapagos CRO in 2014)
• Covance (Acquired by LabCorp in 2015)
• Cyprotex
• Domainex
• Evotec
• GenScript
• Pharmaceutical Product Development (PPD)
• Quintiles
• Selcia
• Viva Biotech
• WIL Research Laboratories
• WuXi AppTec
In general, a company profile gives you the following information:
• Drug discovery revenue forecast from 2015 to 2025
• Historical and recent revenue figures
• Description of services and products
• Assessment of recent developments - mergers and acquisitions (M&A), collaborations, partnerships and alliances
Discover capabilities, progress, and commercial prospects, helping you stay ahead.
To see a report overview please email Sara Peerun on [email protected]
How the Drug Discovery Outsourcing Market Forecast 2015-2025: Opportunities for Leading Companies report delivers
In summary, our 223-page report gives you the following knowledge:
• Revenue forecast to 2025 for the world drug discovery outsourcing market and 4 leading submarkets - Discover the industry's prospects, finding promising areas for investment and revenues.
• Revenue forecasts to 2025 for the leading 13 national markets - US, Japan, Germany, France, UK, Italy, Spain, Brazil, Russia, China, India, South Korea, Mexico and the Rest of the World
• Assessment of 14 leading companies - hear about collaborations, partnerships, contracts and alliances and predicted revenues to 2025
• Analysis of what stimulates and restrains that industry and market - assess challenges and strengths, helping you compete and get advantages.
• View opinions from our survey, seeing interviews with leading drug discovery outsourcing experts.
You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our study you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions.
Visiongain's study is for everybody needing commercial analyses for the drug discovery outsourcing market and leading CROs that offer these services. You find data, trends and predictions. Please order our report now.
To request an exec summary of this report please email Sara Peerun at [email protected] or call Tel: +44 (0) 20 7336 6100
Or click on https://www.visiongain.com/Report/1416/Drug-Discovery-Outsourcing-Market-Forecast-2015-2025
Companies Listed In This Report
AbbVie
Actavis
Acurian
ADDC
Advion Bioanalytical Labs
Albany Molecular Research (AMRI)
Alexion
AMRI
Apredica
Aptuit
Argenta
Ark Therapeutics
AstraZeneca
Auspherix
Bayer
Behrman Capital
Bio City
BioDuro
BioFocus
BioPontis Alliance
Boehringer Ingelheim Pharmaceuticals
Bristol Myers Squibb
C4X Discovery (C4XD)
Cantab
Caprion Proteomics
Catalent Pharma Solutions
ChanTest
Charles River Laboratories
CHDI Foundation
ChemBridge
ChemDiv
Convergence Pharmaceuticals
Covance
LabCorp
CRL
CTSI
Cyprotex
Daiichi Sankyo
Domainex
Synthesis Med Chem
Elan
Eli Lilly
Enamine
Evotec
Fidelity Growth Partners India (FGPI)
Forma Therapeutics
Fraunhofer Institute for Molecular Biology and Applied Ecology
Galapagos
GE Healthcare
Genentech
GenScript
Great Lakes Chemical Corp
GSK
HD Biosciences
Horizon
Hypha Discovery
ICON
IMI
Immatics
Janssen Pharmaceuticals
Johnson & Johnson Innovation
KDDF
Kellogg Company
Knopp Biosciences
LabCorp
Laurus Labs
Marshall University
MedImmune
Merck
Midwest BioResearch
MRC Technology
NextCODE Health
Ono
Oxford Asymmetry International
Parexel
Pharmaceutical Product Development (PPD)
Proteros
Quintiles
Ricerca Biosciences LLC
Roche
Rules-Based Medicines
Sanofi
Scynexis Europe
Selcia
ShangPharma Corporation
Shire US Manufacturing Inc
Siena Biotech
SmithKline Beecham
Tigermed Consulting
UC San Francisco (UCSF)
UCB Pharma
Viva Biotech
VivoPath
WCCT Global
WIL Research Laboratories
WuXi AppTec
X-Chem
Other Organisations Mentioned in This Report
ABO
Academic Consortium: St George's, University of Manchester
Academy of Military Medical Sciences
Beijing Genomics Institute
Biomedical Catalyst Fund
Bundesverband Medizinischer Auftragsinstitute (BVMA)
Cambridge University
Dundee University
Indiana Clinical and Translational Sciences Institute (CTSI)
Innovative Medicine Initiative (IMI)
JOINN Laboratories
National Centre of Biomedical Analysis
National Institute for Food and Drug Control
North Carolina University
PhRMA (Pharmaceutical Research and Manufacturers of America)
The European CRO Federation (EUCROF)
The Food and Drug Administration FDA (U.S)
The Korea Drug Development Fund (KDDF)
The Royal Society of Chemistry
The Russian Corporation of Nanotechnologies
The University of Edinburgh
The University of Oxford
The Wellcome Trust
University of North Carolina
US National Institutes of Health (NIH)
To see a report overview please email Sara Peerun on [email protected] or call Tel: +44 (0) 20 7336 6100.
SOURCE Visiongain
Share this article